QQ客服 官方微博 反馈留言

	Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non–small-cell Lung Cancer in China
	Xiaoyou Li; Muhammad Abbas; Yun Li; Yue Teng; Ying Fang; Shaorong Yu; Yi Wen; Li Wang; Meiqi Shi
刊名	Clinical Therapeutics
	2019
关键词	bevacizumab brain metastasis maintenance therapy nonsquamous non–small-cell lung cancer (NS-NSCLC) pemetrexed-platinum doublet pleural effusion
ISSN号	0149-2918;1879-114X
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4746437
专题	湖南大学
作者单位	1.Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China 2.Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China 3.Medbanks Network Technology Co, Ltd, Beijing, China
推荐引用方式 GB/T 7714	Xiaoyou Li,Muhammad Abbas,Yun Li,et al. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non–small-cell Lung Cancer in China[J]. Clinical Therapeutics,2019.
APA	Xiaoyou Li.,Muhammad Abbas.,Yun Li.,Yue Teng.,Ying Fang.,...&Meiqi Shi.(2019).Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non–small-cell Lung Cancer in China.Clinical Therapeutics.
MLA	Xiaoyou Li,et al."Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non–small-cell Lung Cancer in China".Clinical Therapeutics (2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。